PARP inhibitors: Current status and implications for anticancer therapeutics

Infectious Agents and Cancer

Volumn 8, Issue 1, 2013, Pages

  Usmani, Hadi ^a   Hussain, Syed Ather ^a   Sheikh, Asfandyar ^a,b  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b Pakistan Research Evolution Scientific Society   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

AG 014699S; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; GEMCITABINE; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; RUCAPARIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; HUMAN; METASTATIC MELANOMA; MONOTHERAPY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA BINDING; TARGET CELL DESTRUCTION; TRIPLE NEGATIVE BREAST CANCER;

EID: 84888597310     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-8-46     Document Type: Article

References (21)

1. PARP inhibitors in cancer therapy: an update. Papeo G, Casale E, Montagnoli A, Cirla A, Expert Opin Ther Pat 2013 23 4 503 514 10.1517/13543776.2013.768615 23379721
2. Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD + into a nuclear signal. Kim MY, Zhang T, Kraus WL, Genes Dev 2005 19 17 1951 1967 10.1101/gad.1331805 16140981 (Pubitemid 41247953)
3. Chemopotentiation by PARP inhibitors in cancer therapy. Tentori L, Graziani G, Pharmacol Res 2005 52 1 25 33 10.1016/j.phrs.2005.02.010 15911331 (Pubitemid 40725597)
4. Sensing DNA damage by PARP-like fingers. Petrucco S, Nucleic Acids Res 2003 31 23 6689 6699 10.1093/nar/gkg890 14627802 (Pubitemid 37508776)
5. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG, Cancer Res 1993 53 17 3976 3985 8358726 (Pubitemid 23267698)
6. PARP inhibitors and cancer therapy. Curtin NJ, Poly (ADP-ribosyl) ation United States: Springer 2006 218 233
7. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. D'Amours D, Desnoyers S, D'Silva I, Poirier GG, Biochem J 1999 342 Pt 2 249 268 10455009 (Pubitemid 29425344)
8. The PARP superfamily. Ame JC, Spenlehauer C, de Murcia G, Bioelectromagnetics 2004 26 8 882 893 (Pubitemid 39128102)
9. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, Dawson VL, Proc Natl Acad Sci USA 2006 103 48 18314 18319 10.1073/pnas.0606528103 17116881 (Pubitemid 44871655)
10. PARP is important for genomic stability but dispensable in apoptosis. Wang ZQ, Stingl L, Morrison C, Jantsch M, Los M, Schulze-Osthoff K, Wagner EF, Genes Dev 1997 11 18 2347 2358 10.1101/gad.11.18.2347 9308963 (Pubitemid 27408532)
11. PARP and cancer-if it's broke, don't fix it. Carey LA, Sharpless NE, N Engl J Med 2011 364 3 277 279 10.1056/NEJMe1012546 21208102
12. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. Nature 2005 434 7035 917 921 10.1038/nature03445 15829967 (Pubitemid 40559006)
13. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T, Nature 2005 434 7035 913 917 10.1038/nature03443 15829966 (Pubitemid 40559005)
14. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al. N Engl J Med 2009 361 2 123 134 10.1056/NEJMoa0900212 19553641
15. Advances in using PARP inhibitors to treat cancer. Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH, BMC Med 2012 10 25 10.1186/1741-7015-10-25 22401667
16. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, et al. Ann Oncol 2013 24 5 1416 1418 10.1093/annonc/mdt074 23524863
17. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C, N Engl J Med 2011 364 3 205 214 10.1056/NEJMoa1011418 21208101
18. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL, Breast Cancer Res Treat 2012 134 2 649 659 10.1007/s10549-012-2106-5 22678161
19. A phase II study of the potent PARP inhibitor, rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, et al. Cancer Chemother Pharmacol 2013 71 5 1191 1199 10.1007/s00280-013-2113-1 23423489
20. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y, Cancer Res 2012 72 21 5588 5599 10.1158/0008-5472.CAN-12-2753 23118055
21. Mechanisms of resistance to PARP inhibitors-three and counting. Fojo T, Bates S, Cancer Discov 2013 3 1 20 23 10.1158/2159-8290.CD-12-0514 23319766